Neuroimmunomodulatory and neuroprotective effects of the flavonoid apigenin in <i>in vitro</i> models of neuroinflammation associated with Alzheimer’s disease by Dourado, Naiara Silva et al.
ORIGINAL RESEARCH
published: 15 May 2020
doi: 10.3389/fnagi.2020.00119
Edited by:
George E. Barreto,
University of Limerick, Ireland
Reviewed by:
Shih-Heng Chen,
National Institute of Environmental
Health Sciences (NIEHS),
United States
Luca Steardo,
University Magna Graecia of
Catanzaro, Italy
Haroon Badshah,
Abdul Wali Khan University Mardan,
Pakistan
*Correspondence:
Silvia Lima Costa
costasl@ufba.br;
costasl2011@gmail.com
Received: 27 December 2019
Accepted: 08 April 2020
Published: 15 May 2020
Citation:
Dourado NS, Souza CS, de
Almeida MMA, Bispo da Silva A, dos
Santos BL, Silva VDA, De Assis AM,
da Silva JS, Souza DO, Costa MFD,
Butt AM and Costa SL
(2020) Neuroimmunomodulatory and
Neuroprotective Effects of the
Flavonoid Apigenin in in vitro Models
of Neuroinflammation Associated
With Alzheimer’s Disease.
Front. Aging Neurosci. 12:119.
doi: 10.3389/fnagi.2020.00119
Neuroimmunomodulatory and
Neuroprotective Effects of the
Flavonoid Apigenin in in vitro Models
of Neuroinflammation Associated
With Alzheimer’s Disease
Naiara Silva Dourado1, Cleide dos Santos Souza1,2, Monique Marylin Alves de Almeida1,
Alessandra Bispo da Silva1, Balbino Lino dos Santos1,3, Victor Diogenes Amaral Silva1,4,
Adriano Martimbianco De Assis4,5,6, Jussemara Souza da Silva6, Diogo Onofre Souza4,6,
Maria de Fatima Dias Costa1,7, Arthur Morgan Butt8 and Silvia Lima Costa1,4,7*
1Laboratory of Neurochemistry and Cellular Biology, Institute of Health Sciences, Av. Reitor Miguel Calmon S/N, Federal
University of Bahia (UFBA), Salvador, Brazil, 2Sheffield Institute of Translational Neuroscience (SITraN), The University of
Sheffield, Sheffield, United Kingdom, 3College of Nursing, Federal University of Vale do São Francisco (UNIVASF), Petrolina,
Brazil, 4INCT for Excitotoxicity and Neuroprotection (INCT-EN, BR), Porto Alegre, Brazil, 5Postgraduate in Health and
Behavior, Catholic University of Pelotas (UCPEL), Pelotas, Brazil, 6Department of Biochemistry, Institute of Basic Health
Sciences, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil, 7Instituto Nacional de Ciência e Tecnologia
em Excitotoxicidade e Neuroproteção (INCT)—Translational Neuroscience (INCT-TN, BR), Porto Alegre, Brazil, 8School of
Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, United Kingdom
Neurodegenerative disorders (ND) are characterized by the progressive and irreversible
loss of neurons. Alzheimer’s Disease (AD) is the most incident age-related ND, in
which the presence of a chronic inflammatory compound seems to be related to
its pathogenesis. Different stimuli in the central nervous system (CNS) can induce
activation, proliferation, and changes in phenotype and glial function, which can
be modulated by anti-inflammatory agents. Apigenin (4,5,7–trihydroxyflavone) is a
flavonoid found in abundance in many fruits and vegetables, that has shown
important effects upon controlling the inflammatory response. This study evaluated
the neuroprotective and neuroimmunomodulatory potential of apigenin using in vitro
models of neuroinflammation associated with AD. Co-cultures of neurons and glial
cells were obtained from the cortex of newborn and embryonic Wistar rats. After
26 days in vitro, cultures were exposed to lipopolysaccharide (LPS; 1 µg/ml), or
IL-1β (10 ng/ml) for 24 h, or to Aβ oligomers (500 nM) for 4 h, and then treated
with apigenin (1 µM) for further 24 h. It was observed that the treatment with
apigenin preserved neurons and astrocytes integrity, determined by Rosenfeld’s staining
and immunocytochemistry for β-tubulin III and GFAP, respectively. Moreover, it was
observed by Fluoro-Jade-B and caspase-3 immunostaining that apigenin was not
neurotoxic and has a neuroprotective effect against inflammatory damage. Additionally,
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apigenin reduced microglial activation, characterized by inhibition of proliferation (BrdU+
cells) and modulation of microglia morphology (Iba-1 + cells), and decreased the
expression of the M1 inflammatory marker CD68. Moreover, as determined by RT-qPCR,
inflammatory stimuli induced by IL-1β increased the mRNA expression of IL-6, IL-1β,
and CCL5, and decreased the mRNA expression of IL-10. Contrary, after treatment
with apigenin in inflammatory stimuli (IL-1β or LPS) there was a modulation of the mRNA
expression of inflammatory cytokines, and reduced expression of OX42, IL-6 and gp130.
Moreover, apigenin alone and after an inflammatory stimulus with IL-1β also induced the
increase in the expression of brain-derived neurotrophic factor (BDNF), an effect that may
be associated with anti-inflammatory and neuroprotective effects. Together these data
demonstrate that apigenin presents neuroprotective and anti-inflammatory effects in vitro
and might represent an important neuroimmunomodulatory agent for the treatment of
neurodegenerative conditions.
Keywords: neuroinflammation, neuroprotection, anti-inflammatory, microglia, flavonoids
INTRODUCTION
Neurodegenerative disorders (ND) age-related represent a
serious public health problem in which incidence has increased
due to augmented population aging. These disorders are
associated with the progressive loss of neurons (Procaccini
et al., 2016) and studies suggest that exacerbated inflammatory
response could be the major cause behind neurodegeneration
(Doty et al., 2015).
Among the cells that comprise the central nervous system
(CNS), astrocytes and microglia have been proved for playing
a critical role in physiology and disease (Allen and Barres,
2009), because these glial cells are capable to respond actively
against toxins, infections and injuries to the CNS (Burda
and Sofroniew, 2014; Kinney et al., 2018). Glial activation
is a protective mechanism that regulates tissue repair in
the early stage of neurodegeneration (Streit, 2005). However,
excessive and prolonged activation contributes to a chronic
neuroinflammatory response (Kraft and Harry, 2011), that
might be involved in the onset and progression of most ND,
such as Amyotrophic lateral sclerosis, Parkinson’s disease and
Alzheimer’s disease (Heneka et al., 2015; Ghadery et al., 2017;
Shi and Holtzman, 2018; Jara et al., 2019; McCauley and Baloh,
2019). According to van Horssen et al. (2019), microglial and
astrocytic activation leads to the production of inflammatory
mediators such as cytokines, chemokines, reactive oxygen and
nitrogen species, which eventually contribute to neuronal death.
Beyond the diseases that imply greater socioeconomic impact,
Alzheimer’s disease (AD) is the most frequent neurodegenerative
disorder in the world characterized by the accumulation of
β-amyloid (Aβ) protein in the brain parenchyma, the formation
of neurofibrillary tangles, glial activation and production of
inflammatory mediators such as NO, interleukin 1β (IL-1β),
interleukin 6 (IL-6) and tumor necrosis factor-α (TNF-α; Zotova
et al., 2013; Alasmari et al., 2018). Despite new therapeutic
approaches carried out over the past few years, treatments
for AD and other ND are still limited and do not stop the
progression, but mainly control symptoms. Thus, targeting
neuroinflammation represents one of the most promising
disease-modifying treatments against ND.
Recently recognized for their powerful effect upon controlling
inflammation, flavonoids have been largely studied as an
alternative to treat inflammatory conditions. These compounds
are derived from plant secondary metabolism and are widely
distributed in the plant kingdom (Agati et al., 2011). They
act by interfering with several intracellular processes, such as
increasing the activation of antioxidant enzymes (Magalingam
et al., 2013), additionally to the suppression of lipid peroxidation
(Schinella et al., 2010) and inhibition of pro-inflammatory and
proapoptotic mediators (Zhang et al., 2011; Raza et al., 2013).
Studies suggest the correlation of dietary flavonoid consumption
with the reduction of dementia levels (Beking and Vieira, 2010;
Shahidi and Ambigaipalan, 2015; Terahara, 2015).
Apigenin (4,5,7–trihydroxyflavone) is a flavonoid belonging
to the class of flavones, found in abundance in fruits and
teas (McKay and Blumberg, 2006; Gazola et al., 2015).
Studies have shown several biological activities associated with
apigenin treatment, such as antioxidant (Han et al., 2012),
anti-inflammatory (Lee et al., 2015), neurogenic (Souza et al.,
2015), neuroprotective (Balez et al., 2016), and antitumor
(Coelho et al., 2019). Importantly, apigenin can cross the blood-
brain barrier (Popovi´c et al., 2014), which is of great significance
to treat CNS disorders. However, despite studies have shown its
diverse biological activities in different models, the mechanisms
by which apigenin promotes neuroprotection remain elusive.
In this light, in this study, we used a well-established
co-culture model of neurons and glial cells (Silva et al.,
2013) to investigate the anti-inflammatory and neuroprotective
activity of the flavonoid apigenin, in three different models of
neuroinflammation induced by lipopolysaccharide (LPS; classic
neuroinflammation), IL-1β or Aβ oligomers. Overall, it was
demonstrated that apigenin is not neurotoxic in the tested
concentration and has neuroprotective potential, evidenced by
the reduction of caspase 3 activation and the increase in neuronal
viability, and this effect is thought to be mainly through the
control of microglia and astrocyte inflammatory response.
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MATERIALS AND METHODS
Neuron/Glial Cells Co-cultures
Glial cells and neurons were obtained from the brain
hemispheres of Wistar rats as described previously (Dos
Santos Souza et al., 2018). The animals were provided by
the Animal Facilities of the Department of Physiology of the
Institute of Health Sciences of the Federal University of Bahia
(Salvador, Brazil). All experiments were performed following
the local Ethical Committee for Animal Experimentation of
the Health Sciences Institute (CEUA, Protocol n◦027/2012).
For the co-cultures, glial cells were obtained from the cortex of
neonate animals, aged 1 to 2 days, and neurons were obtained
from embryos with 14–16 day-old embryos (Figure 1). Cerebral
hemispheres were removed aseptically. Meninges and blood
vessels were removed from each cortex, and then the material
was mechanically dissociated and filtered into a sterile 75 mm
diameter Nitex membrane (R&Dr). Dissociated cells were then
cultured in DMEMHAM F12 medium (Gibcor), supplemented
with amino acids (2 mM L-glutamine and 0.011 g/l pyruvate,
Merck), 10% fetal bovine serum (FBS, Gibcor), 3.6 g/l Hepes
(Merck), 33 mM glucose (Cultilab, SP, Brazil), antibiotics
(100 IU/ml penicillin G and 100 µg/ml streptomycin, Gibcor),
and cultured in 100-mm Ø plates (TPP) in a humidified
atmosphere with 5% CO2 at 37◦C. The culture medium was
changed every 48 h and cells were cultured for 15 days. Cells were
then washed three times with PBS, detached with trypsin solution
at 37◦C (Trypsin/EDTA, Merck), plated at a density of 1 × 105
cell/cm2 as described previously (Dos Santos Souza et al., 2018)
and maintained in culture for 72 h. After incubation, neurons
obtained from cerebral hemispheres of 14- to 16-day-old Wistar
rat embryos, using the same method described above for glial
isolation, were suspended in supplemented DMEM/HAM F12
(Gibcor) and seeded at half the number of glial cells (5 × 104
cells/cm2) onto the glial monolayer. The co-cultures were
incubated in a humidified atmosphere with 5% CO2 at 37◦C for
8 days in vitro and the medium changed every 48 h.
Drugs and Treatments
Flavonoid apigenin (4′,5,7-trihydroxyflavone) adopted in this
work was purchased commercially (Sigma–Aldrich, St. Louis,
MO, USA 97% purity A3145). It was dissolved in dimethyl
sulfoxide (DMSO, Sigma–Adrich, St. Louis, MO, USA) to a
stock concentration of 100 mM and kept protected from light
at a temperature of −20◦C. Final dilution was obtained at the
time of treatment by diluting the concentrated solution directly
into the culture medium. Cells were exposed to flavonoids at
a final concentration of 1 µM. Control cultures were treated
with DMSO in a volume equivalent to apigenin concentration
(0.01%). Experimental analyses were performed 24 h after the
treatment. To induce inflammatory damage, co-cultured cells
were exposed for 24 h to LPS (1 µg/ml, Sigma Chemical
Company L2880) or Interleukin 1 beta (IL-1β, 10 ng/ml; R&D
Systems 501-RL-010), or for 4 h to Aβ oligomers (500 nM,
American Peptide). The experimental design is illustrated in
Figure 1. Final dilution of LPS and IL-1β was obtained at
the time of treatment by diluting the stock solution directly
into the culture medium. The concentration and exposure
time adopted followed established protocols (Radesäter et al.,
2003; Moraes et al., 2015). Solubilization of the β-amyloid
peptide from synthetic Aβ1–42 peptide (American Peptide)
was performed according to protocol already established (De
Felice et al., 2008; Lourenco et al., 2013), and was diluted in
culture medium to obtain a 500 nM solution from a stock
solution (100 µM). The concentration and exposure time
adopted followed established protocols described in the literature
(Lourenco et al., 2013). In brief, Aβ1–42 peptide was solubilized
at 1 mM in ice-cold 1,1,1,3,3,3 hexafluoro-2-propanol (HFIP;
Merck) and the resulting clear colorless solution was incubated
at room temperature for 60 min. The solution was then placed
on ice for 10 min and aliquoted (25 µl of HFIP solution to obtain
0.133 mg Aβ). Microtubes were left open in the laminar flow
hood for 12 h for evaporation of HFIP. The complete elimination
of HFIP was done by SpeedVacr centrifugation for 10 min.
Aliquots containing Aβ films were stored at −20◦C for later use.
Aβ oligomer preparations were made from Aβ films resuspended
in 2% dimethylsulfoxide (DMSO; Sigma-Adrich, St. Louis, MO,
USA) to obtain a solution at 5 mM. This solution was then
diluted in 100 µM sterile PBS and incubated at 4◦C for 24 h.
After incubation, the preparation was centrifuged at 14,000 g for
10 min at 4◦C to remove insoluble Aβ aggregates (fibrils). The
centrifugation supernatant containing the oligomers was kept at
4◦C until use. To determine the concentration of oligomers in the
preparations, the BCA Kit (BIO-RAD) was used.
Fluoro-Jade B Staining
The neuroprotective potential of apigenin was assessed with
the Fluoro-Jade B assay (FJB, Millipore, AG310). This staining
was used to evaluate neuronal death. Cells were cultured
in 96-well black bottom plates (Corning Incorporated, 3603)
and treated as described. After treatments the co-culture,
supernatants were removed and the cells were fixed with
ethanol at 4◦C for 10 min, washed three times with PBS, and
permeabilized with 0.3% Triton X-100 in PBS (Merck) for
10 min. After this time, the cultures were washed three times
with distilled water and incubated with 0.001% FJB solution
for 30 min at room temperature (RT), under slow agitation
and protected from the light. After incubation, the cells were
washed three times with PBS and incubated for 5 min at RT
in the dark with 5 µg/ml 4,6-diamidino-2-phenylindole (DAPI)
for nuclear staining, and then washed three times with PBS.
Analyses were performed on a spectrophotometer (VarioskanTM
Flash Multimode Reader, Thermo Plate), and the fluorescence
intensity of each sample was measured at 480 nm for FJB and
350 nm for DAPI. The value of absorbance of FJB of each well
was normalized to the DAPI absorbance in the same well. Three
independent experiments were performed. Thereafter, cells were
analyzed using a fluorescence microscope (Leica, DFC7000).
Quantification was analyzed with ImageJ 1.33u.
Rosenfeld’s Staining
Glial and neuronal morphological changes in response to
inflammatory stimuli and treatment with apigenin were
primarily assessed by Rosenfeld’s staining. After exposure of the
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FIGURE 1 | Experimental design. Neurons/glia co-cultures were obtained from the cortex of Wistar rats. After 26 days of cultivation, the cultures were treated with
either Aβ oligomers (500 nM) for 4 h or IL-1β (10 ng/ml) or LPS (1 µg/ml) for 24 h and then treated with apigenin (1 µM) and analyzed after 24 h treatments.
cells to the treatments, the culture medium was discarded and
the cells were washed three times with phosphate-buffered saline
(PBS, Sigma) and then fixed in 4% paraformaldehyde for 20 min
at room temperature (RT), after that, cultures were washed
three times with PBS. Fixed cells were stained by the protocol
established by Rosenfeld (Rosenfeld, 1947). Rosenfeld’s reagent
was added and incubated for 20 min at room temperature. Three
independent experiments were performed. Thereafter, the plates
were rinsed with water, air-dried, analyzed in an optic phase
microscope (Nikon; Figures 2A,C).
Immunocytochemistry
Glial and neuronal response to inflammatory stimuli and
treatment with apigenin was assessed by immunocytochemistry
using the following primary antibodies: anti-β-Tubulin III
(mouse, 1:500; BioLegend, 801202), anti-GFAP (rabbit, 1:300;
DAKO, Z0334), anti-Iba-1 (ionized calcium-binding adaptor
molecule 1; rabbit, 1:200; Wako, 019-19741), anti-CD68 (rat,
1:100; Abcam, ab53444), anti-active caspase-3 (rabbit, 1:300;
Chemicon, ab3623), anti-CD11b/c (OX42; mouse, Abcam,
ab1211), anti-IL-6 (rabbit, 1:500; Abcam, ab6672) and anti-gp130
(rabbit, 1:500; Abcam, ab6672). After exposure of the cells to
the treatments, the culture medium was discarded and the cells
were washed three times with phosphate-buffered saline (PBS,
Sigma) and then fixed in 4% paraformaldehyde for 20 min
at room temperature (RT). After that cultures were washed
three times with PBS and permeabilized with Triton X-100
(0.3%) in PBS for 15 min and then washed again with PBS
three times for 5 min. After this time, non-specific binding
sites were blocked by incubation with PBS containing 5%
bovine serum albumin (BSA; Sigma–Adrich, St. Louis, MO,
USA) for 1 h. After blocking, samples were incubated with
primary antibodies diluted in PBS containing 1% of BSA in
a humid chamber at 4◦C for 12 h. Subsequently, cells were
washed three times with PBS and incubated with secondary
antibodies diluted in PBS containing 1% of BSA and kept
under slow agitation for 1 h at RT, protected from the light.
The cells were washed with PBS three times and incubated
with 5.0 µg/ml 4,6-diamidino-2-phenylindole (DAPI, Molecular
Probes, Eugene, OR, USA) for nuclear staining for. The cell
coverslips were then washed three times in PBS and mounted
on slides containing 80% glycerol N-propyl gallate mounting
medium (Sigma–Adrich, St. Louis, MO, USA). Staining was
visualized on a fluorescence microscope (Leica, DFC7000) and
(Leica, SP8 confocal). Images were captured with a 20× or
40× objective. Three independent experiments were performed.
Quantification was analyzed with ImageJ 1.33u. The following
secondary antibodies were used at the indicated dilutions: Alexa
Fluor 488-conjugated goat anti-mouse IgG (1:500; Molecular
Probes, A11001), Alexa Fluor 594-conjugated goat anti-rabbit
IgG (1:500; Molecular Probes, A11012), Alexa Fluor 488 goat
anti-rabbit IgG [H&L] (1:500; Molecular Probes A11008), Alexa
Fluor 555-conjugated goat anti-rat IgG (1:500; Molecular Probes,
A21434) and Alexa Fluor 594-conjugated goat anti-rabbit IgG
(1:500, Molecular Probes A11012). The quantification was
performed by analyzing the total number of positive cells
(per marker), divided by the total number of nuclei (DAPI
positive)× 100.
Bromodeoxyuridine Cell Proliferation
Assay
To evaluated proliferation was using the Bromodeoxyuridine
(BrdU) cell proliferation assay (Sigma–Aldrich, Inc., St. Louis,
MO, USA). BrdU (10 µM) was added to the wells since
each treatment had started. Cells were incubated for 2 h in a
humidified atmosphere of 95% air and 5% CO2 at 37◦C. Cells
were fixed andDNAwas denatured by treatment with denaturing
solution (2 N HCl) for 20 min at room temperature. Anti-BrdU
monoclonal antibody (mouse, 1:200, Sigma–Adrich, St. Louis,
MO, USA B8434) diluted in PBS was pipetted into the wells and
allowed to incubate for 1 h. Unbound antibody was washed away
and cells were incubated with Alexa Fluor 546-conjugated goat
anti-mouse IgG (1:500; Molecular Probes, A11003), diluted in
PBS-T for 1 h under slow agitation at room temperature. After
incubation, the cell nuclei were stained with DAPI (5 µg/ml) for
10 min at room temperature. All reagents were used following
the manufacturer’s instructions. Experiments were performed in
triplicate. Thereafter, cells were analyzed using a fluorescence
microscope (Leica, DFC7000) Quantification was analyzed with
ImageJ 1.33u software (Wayne Rasband, National Institutes of
Health, Bethesda, MD, USA).
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FIGURE 2 | Apigenin preserves neuronal and astrocyte morphology. Effects
of apigenin (API, 1 µM) treatment on the integrity of neurons and astrocyte
reactivity after lipopolysaccharide (LPS; (A,B, 1 µg/ml) and IL-1β (C,D, IL-1β
10 ng/ml) inflammatory stimuli. Morphological changes were primarily
assessed by analyzing the Rosenfeld’s staining (A,C). The patterns of
expression of the cytoskeletal protein β-tubulin III (β-tubIII, green) specific of
neurons, and the cytoskeletal protein GFAP (red) marker of astrocyte
morphology and reactivity were determined by immunocytochemistry and
confocal analysis after 24 h treatments; control cultures were treated with
dimethyl sulfoxide (DMSO; 0.01%) and nuclear chromatin was stained with
4,6-diamidino-2-phenylindole (DAPI; blue). Obj. 40×, scale bar: 50 µm; white
arrows indicate neurons without neurites.
Quantitative RT-PCR
To evaluate gene expression for proteins of interest, after
the treatment period, the culture medium was removed
and then total RNA was extracted with Trizolr reagent
(Invitrogen, Life Technologies, 15596026). Extraction was
performed according to the manufacturer’s specifications.
Total RNA purity and concentration were determined by
spectrophotometric analysis using KASVI Nano Spectrum
(cat# K23-0002). DNA contaminants were removed by
treating the RNA samples with DNase using the Ambion
DNA-free kit (cat# AM1906, Life TechnologiesTM). For
cDNA synthesis, SuperScriptr VILOTMMasterMix (cat#
MAN0004286, InvitrogenTM, Life Technologies) was used in
a 20-µl reaction with a concentration of 2.5 µg of total RNA,
following the manufacturer’s instructions. Quantitative real-time
PCR (qPCR) was performed using Taqmanr Gene Expression
Assays (Applied Biosystems, Foster City, CA, USA) containing
two primers to amplify the sequence of interest, a specific
Taqmanr MGB probe and TaqMan Universal Master Mix II
with UNG (cat# 4440038 Invitrogen, Life TechnologiesTM).
The assays corresponding to the genes quantified in this
study were IL-1β (Rn00580432_m1), IL-6 (Rn01410330_m1),
CCL5 (Rn00579590_m1), IL-10 (Rn00563409_m1), brain-
derived neurotrophic factor (BDNF; Rn02531962_s1), and
NTF4 (Rn00566076_s1). Real-time PCR was performed using
the Quant Studio 7 FlexTMReal Time PCR System (Applied
Biosystems, CA, USA). The thermocycling conditions were
performed according to the manufacturer’s specifications.
The actin beta (Actb; Rn00667869_m1) and hypoxanthine
phosphoribosyltransferase 1 (HPRT1; Rn01527840_m1) targets
were used as reference genes (endogenous controls) for
normalization of gene expression data. Data were analyzed
using the 2−∆∆Ct method. The results represent the average of
three independent experiments.
Statistical Analyses
The results were analyzed by the GraphPad Prism 5, statistical
program (CA, USA). It was analyzed whether the values came
from a Gaussian distribution. To determine the statistical
difference between the groups, we performed one-way analysis
of variance (ANOVA) followed by Student-Newman–Keuls
post-test for normal samples. For non-normal samples, an
analysis was performed using Kruskal–Wallis followed by
Dunn’s post-test. Confidence intervals were defined at a 95%
confidence level (p < 0.05 was considered to be statistically
significant). Fold change was calculated by dividing the average
(mean) value of the experimental group by that of the control
group. In all figures, error bars represent SEM of at least
three independent experiments.
RESULTS
Apigenin Preserves Neuron and Astrocyte
Morphology After LPS and IL-1β-Induced
Inflammatory Stimuli
LPS a component of the gram-negative bacteria cell membrane,
is known to be a potent inducer of the inflammatory response
via toll-like receptor 4 (Park and Lee, 2013; Xu et al., 2017) and
according to Jin et al. (2017), the IL-1β is a proinflammatory
cytokine that plays a key role in the initiation and development
of a complex cellular inflammatory cascade. Excessive IL-1β
production in the CNS, mainly by glial cells, is associated with
neuroinflammation found in neurodegenerative processes. Here,
we investigate the effects of flavonoid apigenin against classical
neuroinflammation produced by LPS and against inflammatory
damage produced by cytokine IL-1β in glia/neurons co-cultures
in terms of preservation of neuronal integrity, modulation of
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glial (astrocyte and microglia) activation and inflammatory
signaling (Figure 2). Glial and neuronal Morphological changes
in response to inflammatory stimuli and treatment with apigenin
were primarily assessed by Rosenfeld’s staining a differential
stain used to differentiate nuclear and cytoplasmic morphology
(Figures 2A,C). We observed that in control conditions (0.01%
DMSO), the glial cells represented by light pink cytoplasm and
dark pink big nucleus, the cells look diffused with a polygonal
shape. On the other hand, neurons are represented by a dark
purple cytoplasm with neurites represented by long and fine
purple processes. We do not observe morphological changes in
cells treated with apigenin when compared with control cells.
However, we observed a reduction in the neurites in the neurons
after the treatment with LPS (Figure 2A). On the other hand,
apigenin was able to rescue the neuronal integrity after LPS
treatment. Similar results were observed after the treatment with
IL-1β, where we can observe a reduction in the neurites induced
by IL-1β and a rescue for apigenin (Figure 2C).
To evaluate the effect of apigenin treatment on neurons
integrity after 24 h treatment with LPS or with IL-1β,
immunostaining was performed for β-tubulin III (β-tubIII) a
standard neuronal marker in association with GFAP, a classical
marker of astrocyte reactivity. We observed that apigenin
treatment (1 µM; Figures 2B,D) preserved the neurites network,
maintained neuronal cell body integrity and typical astrocyte
polygonal morphology, similar to the control condition (0.01%
DMSO). After induction of inflammatory stimulus with LPS
(1 µg/ml), the neurites network was not preserved, and only
perinuclear staining was observed, associated with cell bodies
forming irregular clustering (Figure 2B). Also, astrocytes showed
reactive morphology, characterized by the presence of longer
processes with higher GFAP expression (Figure 2B). However,
in cultures treated with apigenin after LPS damage astrocyte
maintained the non-reactive phenotype (similar to that observed
under control conditions and after apigenin treatment) and the
neurons integrity was preserved, as well as their networks of
interconnections, compared to cultures treated with LPS alone.
The effects of apigenin on the integrity of neurons and
astrocytes were confirmed in co-cultures submitted to IL-1β-
induced neuroinflammation (Figure 2D). After induction of
IL-1β stimulus (10 ng/ml), few cells labeled for βtubIII were
observed when compared to the control cultures. Also, it was
verified in astrocytes the emission of cellular processes with high
immunoreactivity to GFAP, characteristic of reactive astrocytes.
However, apigenin treatment after IL-1β damage was able to
maintain the entire neurite network, increase the intensity of
the βtubIII labeling with neuron cluster formation, and preserve
the astrocyte morphology similar to that observed in the control
conditions (Figure 2D).
Apigenin Protects Neurons Against LPS
and IL-1β-Induced Inflammatory Stimuli
To better characterize the neuroprotective potential of apigenin
against neuroinflammation, glia/neurons were exposed to LPS
(1 µg/ml) or IL-1β (10 ng/ml) for 24 h and then treated with
apigenin (1 µM) for additional 24 h, and then labeled with Fluor
Jade-B (FJB) that marks neurons in degeneration (Figures 3A,B).
Apigenin treatment did not change neuronal viability when
compared to control cultures (0.01% DMSO). On the other
hand, induction of damage by LPS led to neuronal degeneration,
with an increase of 0.61 ± 0.14 in the relative fluorescence
intensity (IRF) compared to control. It was observed that
after LPS damage, apigenin treatment reduced IRF to baseline
levels observed in the control condition, also demonstrating its
neuroprotective potential (Figures 3A,B).
To verify the neuroprotective potential of apigenin against
neuroinflammation, immunocytochemistry evaluation of the
presence of active caspase-3 a classical apoptosis marker
in association with β-tubulin III (βtubIII) was performed
(Figures 3C–H). The induction of damage by LPS promoted
caspase-3 activation in 1.6 ± 0.1% of total cells, and 15.8 ± 3.7%
of βtubIII positive neurons (Figures 3C–E). This increase
was significant compared to the control [0.3 ± 0.08% and
3.4 ± 1.1%, respectively (Figures 3C–E)]. On the other hand,
after LPS damage, apigenin treatment significantly reduced
the proportion of caspase-3 positive cells (0.4 ± 0.09%) and
caspase-3/βtubIII positive neurons (3.7± 0.7%) when compared
to cultures treated with LPS alone, and no difference was
observed between this group and the control group. IL-
1β treatment promoted caspase-3 activation in 1.7 ± 0.1%
of total cells and 7.6 ± 1.7% of βtubIII positive neurons
compared to control cultures (0.7 ± 0.2% and 2.3 ± 1.0%,
respectively; Figures 3F–H). However, apigenin treatment after
IL-1β damage reduced the percentage of caspase-3 positive cells
(0.3 ± 0.03%) and double-labeled neurons for caspase-3 and
βtubIII (1.0 ± 0, 4%) when compared to cultures treated with
IL-1β alone. Moreover, treatment with 1 µM apigenin did
not induce caspase-3 activation compared to control (DMSO
0.01%). These data suggest that apigenin does not induce cell
death in glia/neurons co-cultures and disrupts the progression
of apoptosis in a neuroinflammation model. Together these
findings demonstrate the neuroprotective and glial modulatory
potential of the flavonoid in conditions of inflammatory stimuli
and neuronal damage.
Apigenin Modulates Microglial Activation
Profile After Inflammatory Stimuli
To evaluate if the neuroprotective effect of apigenin after
different inflammatory stimuli is associated with microglial
activation, first immunostaining was performed for Iba-
1, a classic structural marker of microglia in co-cultures
to characterize changes on morphology, and in association
with BrdU immunostaining, to characterize microglia in
proliferation. After induction of damage by LPS (1 µg/ml),
the percentage of Iba-1 and BrdU positive cells increased
(41.5 ± 4%) compared to the control (21.4 ± 3.2%), which
characterizes microglial proliferation (Figures 4A,B). However,
apigenin treatment after LPS damage significantly reduced the
percentage of positive Iba-1 and BrdU cells (9.4 ± 2.8%)
when compared to co-cultures treated with LPS alone and
did not show statistical significance in the percentage of
these cells when compared to control. Moreover, apigenin
treatment (1 µM) had no significant effect on the proportion
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FIGURE 3 | Apigenin protects neurons against neuroinflammation induced
by LPS and IL-1β. Effects of apigenin (API, 1 µM) treatment on the integrity of
neurons and induction of apoptosis after lipopolysaccharide (LPS) (A–E, 1
µg/ml) or IL-1β (F–H, 10 ng/ml) inflammatory stimuli. (A) Evaluation of
neuronal degeneration by FJB assay in cultures after LPS (1 µg/ml)
inflammatory stimuli. (B) Graph Barr showing neuronal degeneration by
Fluoro-Jade B (FJB) assay. (C,F) The patterns of expression of the
cytoskeletal protein β-tubulin III (β-tubIII, green) specific of neurons, and of the
activated caspase-3 (CASP, red), a marker of cells in apoptosis, were
determined by immunocytochemistry after 24 h treatments. Control cultures
were treated with DMSO (0.01%) and nuclear chromatin was stained with
DAPI (blue). (D,G,E,H) Graphs represent the total population of caspase-3
positive cells, and the population of cells doubly labeled βTubIII and
caspase-3; *statistical significance concerning control (DMSO 0.01%),
p-value < 0.01; #statistical significance in relation to the group treated with
LPS, p-value < 0.01; ** and #statistical significance in relation to the group
treated with IL-1β p-value < 0.001 and p-value < 0.01; Statistical test:
analysis of variance (ANOVA) followed by Student Newman–Keuls test;
results expressed as mean ± standard deviation of FJB fluorescence
intensity; #represents statistical difference compared to control DMSO 0.01%)
with p-value < 0.001 ***represents statistical difference compared to the
group treated with LPS with p-value < 0.001. Values are expressed as the
mean ± SEM (n = 3) and were tested for significance by ANOVA followed by
the Newman–Keuls test. Obj. 40×, scale bar: 50 µm; arrows indicate cells
doubly labeled βTubIII and caspase-3.
of double-labeled cells for Iba-1 and BrdU compared to
control co-cultures.
Modulation of the microglial profile was also evaluated based
on the morphological changes visualized by the Iba-1 protein
immunostaining. We verified that under control conditions
treated with 0.01% DMSO, the microglia presented branched
morphology. Exposure to LPS (1 µg/ml; Figure 4A), was able
to induce phenotypic changes. It was observed that in these
conditions, Iba-1 positive cells showed ameboid morphology.
However, microglia morphology in co-cultures treated with
apigenin after inflammatory stimuli presented a morphological
pattern similar to that observed in the control conditions,
showing branched morphology.
Moreover, to evaluate the effects of apigenin on the
modulation of the microglial profile after inflammatory stimuli
with LPS (1 µg/ml), double immunostaining was performed
for Iba-1 protein and CD68, a specific M1 profile marker in
glia/neurons co-cultures (Figure 4C). After exposure to LPS, an
increase in the proportion of Iba-1 positive cells (16.2 ± 2.6%;
Figure 4D) and CD68 positive microglia (19 ± 4.1%) was
observed compared to the control cultures (8.6 ± 0.9% and
3.6± 1.9%, respectively; Figure 4E). On the other hand, apigenin
(1 µM) treatment after LPS damage reduced significantly the
percentage of Iba-1 positive cells (7.1± 0.6%) and CD68 positive
cells (5.2 ± 1.9%) when compared to cultures treated with LPS
only (Figures 4C,E). No significant effect on the proportion of
microglia and expression of the M1 marker was observed after
apigenin treatment.
To confirm if the neuroprotective effect of apigenin after
different inflammatory stimuli is associated with microglial
activation, we stimulated the cells with IL-1β and then with
apigenin. Similarly to LPS the treatment with IL-1β (10 ng/ml),
was able to induce phenotypic changes in microglial cells
(Figure 4F) evidenced by the ameboid morphology of Iba-1
positive cells. However, microglia morphology in co-cultures
treated with apigenin after inflammatory stimuli induced by
IL-1β (10 ng/ml), presented morphological pattern similar to
that observed in the control conditions, showing branched
morphology (Figure 4F). These results demonstrate that
apigenin reduced microglial proliferation/activation after the
inflammatory stimulus and reaffirm its anti-inflammatory effect.
Apigenin Regulates the Expression of
Inflammatory Mediators in Neurons/Glial
Cells Co-cultures Submitted to IL-1β or
LPS Stimulus
To better characterize the anti-inflammatory effect of apigenin,
co-cultures were exposed to IL-1β (10 ng/ml) for 24 h and
then treated with apigenin (1 µM). After treatments, the
mRNA expression levels of the interleukin 6 (IL-6), C-C
chemokine ligand 5 (CCL5) and IL-1β pro-inflammatory
mediators, the IL-10 regulatory cytokine, the BDNF and
neurotrophin-4 (NTF4) were evaluated by RT-qPCR (Figure 5).
After IL-1β damage induction, there was an increase in IL-
6, CCL5, and IL-1β mRNA expression when compared to
control (Figures 5A–C). After IL-1β damage followed by
apigenin treatment, a reduction in IL-6 levels, when compared
to cultures treated with IL-1β alone (Figure 5A). Although
apigenin treatment induced a reduction in CCL5 and IL-1β
gene expression, it was not significant when compared to
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FIGURE 4 | Apigenin modulates microglial activation profile. Effects of apigenin (API, 1 µM) treatment on the activation of microglia after LPS (A–E, 1 µg/ml), or
IL-1β (F, 10 ng/ml) inflammatory stimuli in glia/neurons co-cultures. Proliferation and changes in morphology, both features of microglial activation were analyzed.
(A,B) Immunocytochemistry for ionized calcium-binding adapter molecule 1 (Iba-1, green), specific of microglia, associated with bromodeoxyuridine (BrdU; red), that
marker cells in proliferation was performed in cultures submitted to inflammatory stimuli with LPS. Graphs (B,D) represents cell population labeled for both Iba-1 and
BrdU; data a represented as mean of percentage ± standard deviation of immunofluorescence labeling of Iba-1 and BrdU cells (C) Immunocytochemistry for Iba-1
(green), associated with CD68 (red), marker of activated microglia/macrophages in a proinflammatory profile was performed after 24 h treatments. (D,E) The graphs
represent the total population of Iba-1 positive cells (microglia) and the population of double-labeled Iba-1 +/CD68 + microglia. (F) Immunocytochemistry for the
cytoskeletal protein Iba-1 (red), was also performed in cultures submitted to inflammatory stimuli with IL-1β; control cultures were treated with DMSO (0.01%) and
nuclear chromatin was stained with DAPI (blue); Obj. 40×, scale bar: 50 µm.; *represents statistical significance in relation to the control (DMSO 0.01%) with
p-value < 0.01; #represents statistically significant difference compared to the group treated with LPS, with p-value < 0.01 and ***represents statistical significance
in relation to the group treated with LPS, with p-value < 0.001. Values are expressed as the mean ± SEM (n = 3) and were tested for significance by ANOVA
followed by the Newman–Keuls test; arrows indicate Iba-1 positive cells showed ameboid morphology.
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FIGURE 5 | Apigenin regulates the expression of inflammatory mediators. Effects of apigenin (API, 1 µM) treatment on expression of inflammatory and neurotrophic
factors by qRT-PCR in glia/neurons co-cultures treated with IL-1β (10 ng/ml). (A–F) mRNA expression for proinflammatory (IL-6, IL-1β) and regulatory interleukins
(IL-10), for chemokine CCL5, for the brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NTF-4) were evaluated 24 h after treatment with apigenin. Effects
of apigenin (API, 1 µM) treatment on expression of inflammatory markers by immunocytochemistry in glia/neurons co-cultures treated with LPS (1 µg/ml). (G)
Immunocytochemistry for IL-6 (green), associated with CD68 (red), marker of activated microglia/macrophages in a proinflammatory profile. (H)
Immunocytochemistry for OX42 (green), associated with gp130 (red), marker of activated microglia/macrophages in a proinflammatory profile. Data were presented
as a median of the relative expression to control cultures *statistical significance in relation to the control (DMSO 0.01%), p-value < 0.01; #statistical significance in
relation to the group treated with IL-1β, p-value < 0.01. Were tested for significance using the Kruskal–Wallis test followed by Dunn’s test.
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cultures treated with IL-1β alone (Figures 5B,C). It was also
observed a reduction in IL-10 expression after IL-1β treatment,
when compared to the control (Figure 5D), and although
apigenin treatment induced an increase in IL10 expression
levels, it was not significant when compared to cultures treated
with IL-1β alone. Moreover, in co-cultures treated only with
apigenin the mRNA expression for both pro-inflammatory and
regulatory factors was not changed. Furthermore, it was observed
that apigenin was able to increase BDNF mRNA expression
(14.4) when compared to control with DMSO (0.01%; 1.0;
Figure 5E). Our results revealed that apigenin was able to induce
increase BDNF mRNA levels in neuronal and glial cell co-
cultures after damage with IL-1β (10.22) when compared to
the IL-1β-treated group and the control condition (Figure 5E).
Neurotrophin NTF4 levels were also evaluated but did not show
alterations between groups (Figure 5F). Since IL-1β induces
microglial activation and increases IL-6 mRNA expression,
we investigated the direct effect of apigenin on inflammatory
markers expression in neurons/glial cells co-cultures submitted
to LPS stimulus. Immunofluorescence for CD68 (microglial
M1 pro-inflammatory marker) and IL-6 (pro-inflammatory
cytokine, M1 marker), OX42 (microglial activation marker) and
Glycoprotein 130 (gp130), a type 1 cytokine receptor that is
within the IL-6 receptor family), showed that inflammatory
stimuli increased OX42, IL-6 and gp130 positive cells, which was
abolished by apigenin treatment (Figures 5G,H).
Apigenin Protects Neurons and Reduces
Astrocyte and Microglial Activation
Induced by Amyloid-β
Neuroinflammation in the brain is a feature in AD, this
chronic inflammation is mainly attributed to microglial
activation and the release of numerous inflammatory mediators
(Kinney et al., 2018). We investigated if apigenin can protect
neurons against Aβ toxicity and if it reduces microglia and
astrocyte activation. After induction of damage with Aβ
(500 nM), the labeling for βtubIII was scarce and the astrocytes
showed prolongations with high GFAP immunoreactivity,
also suggesting glial reactivity (Figure 6A). However, apigenin
treatment after Aβ induced damage was able to increase the
intensity of βtubIII labeling with the formation of neural
clusters and preserved astrocyte morphology and GFAP
expression, patterns similar to control cultures (Figure 6A).
Apigenin treatment alone did not affect βtubIII expression in
neurons and on GFAP expression and astrocyte morphology.
Evaluation of microglial proliferation in co-cultures of
neurons and glial cells exposed to Aβ oligomers (500 nM)
for 4 h and analyzed after additional 24 h demonstrated
that Aβ damage promoted microglial proliferation, with an
increase in the percentage of Iba-1 and BrdU positive cells
(33.7± 7.7%) compared to the control (12± 2%; Figures 6B,C).
However, apigenin treatment after Aβ damage significantly
reduced the percentage of positive Iba-1 and BrdU cells
when compared to co-cultures treated with Aβ alone and
did not show statistical significance in the percentage of
these cells when compared to control. Moreover, apigenin
FIGURE 6 | Apigenin protects neurons and reduces glial activation induced
by amyloid-β. Effects of apigenin (API, 1 µM) treatment on the integrity of
neurons and glial reactivity after Aβ (500 nM) exposure. (A) The patterns of
expression of the cytoskeletal protein β-tubulin III (β-tubIII, green) specific of
neurons, and the cytoskeletal protein GFAP (red) marker of astrocyte
morphology and reactivity were determined by immunocytochemistry analysis
after 24 h treatments; control cultures were treated with DMSO (0.01%) and
nuclear chromatin was stained with DAPI (blue). Obj. 20×, scale bar:
100 µm. (B) Immunocytochemistry for ionized calcium-binding adapter
molecule 1 (Iba-1, green), specific of microglia, associated with BrdU (red),
that marker cells in proliferation was performed in cultures submitted to Aβ.
Obj. 40×, scale bar: 50 µm. (C) Graph represents cell population labeled for
both Iba-1 and BrdU; data are presented as mean of percentage ± standard
deviation of immunofluorescence labeling of Iba-1 and BrdU cells. *represents
statistical significance in relation to the control (DMSO 0.01%) with
p-value < 0.05; #represents statistically significant difference compared to the
group treated with Aβ, with p-value < 0.01. Values are expressed as the
mean ± SEM (n = 3) and were tested for significance by ANOVA followed by
the Newman–Keuls test.
treatment (1 µM) had no significant effect on the proportion
of double-labeled cells for Iba-1 and BrdU compared to
control co-cultures.
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DISCUSSION
Many in vitro models of CNS studies have been developed to
elucidate the mechanisms associated with insults that lead to
neuron death, and thus find better therapeutic targets against
neurodegenerative diseases associated with neuroinflammation.
Among these models, we highlight the co-culture of neuron
and glia, which has several advantages, especially because it
is a method that uses high cell density, which may favor
the generation of neuronal phenotypes that actively interact
with glial cells and mimic tissue-like biological conditions
(Al-Ali et al., 2017).
In this study, we used as experimental model co-cultures
of neurons and glial cells already well established in our
group (Silva et al., 2013) to investigate the anti-inflammatory
and neuroprotective potential of flavonoid apigenin in three
different inflammatory models: induced by LPS (classical
neuroinflammation), IL-1β or Aβ oligomers. In this work, we
demonstrate that apigenin is not neurotoxic at the concentration
tested and has neuroprotective potential, evidenced by the
decreased number of caspase-3+ cells and increased neuronal
viability. In a previous study, we tested the apigenin (10 µM)
activity on embryonic and human-induced pluripotent stem
cells (hPSC). Our data showed that apigenin induced neural
differentiation and promote synaptogenesis (Souza et al., 2015).
Furthermore, in an animal model of spinal cord injury, it
was observed that apigenin treatment (10 and 20 mg/kg; via
ip) recovered neuronal function, and neuroprotective effect
associated with antiapoptotic effects, with reduced caspase
3 expression and an increased ratio of Bcl-2/Bax genes
(Zhang et al., 2014).
In AD, evidences suggest that persistent activation
of microglia and astrocytes, initially triggered by Aβ
oligomers, triggers a chronic inflammatory response that
is partly characterized by the exacerbated production of
proinflammatory cytokines. In turn, these cytokines perpetuated
neuroinflammation and glial activation and consequently
contributed to the progression of neurodegeneration (Stewart
et al., 2010; Heneka et al., 2015). These data support the
hypothesis that the use of anti-inflammatory agents may slow the
progression of this pathology (Daniels et al., 2016). In this sense,
apigenin deserves prominence within the group of plant-derived
polyphenolic compounds, as it demonstrates anti-inflammatory
and neuroprotective potential, presenting itself as a promising
compound for the treatment of neurodegenerative diseases, such
as AD (Balez et al., 2016; Anusha et al., 2017).
Different CNS stimuli may induce activation, proliferation,
and changes in the morphology and function of microglia,
which can be modulated by anti-inflammatory agents, such as
flavone luteolin, which has been shown to promote change in
LPS-exposed BV2 microglial cell lines, from amebic morphology
to branched morphology. This change in morphology has also
been associated with inhibition of NO synthesis and IL-6 mRNA
expression, favoring the M2 phenotype with anti-inflammatory
and neuroprotective characteristics (Dirscherl et al., 2010).
The findings found in this article were similar to this study,
considering that the activation state and the microglia phenotype
may be reflected by its cellular form (Vinet et al., 2012; Tang and
Le, 2016), we show that apigenin it acts as a potent modulator of
themicroglial profile since, after induced inflammatory response,
apigenin treatment generated morphological change from the
ameboid state to branched microglia.
Dynamic changes in microglial phenotypes are associated
with neurodegenerative diseases, and the dichotomy of
the M1/M2 microglial profile is widely accepted, where
such microglia can perform proinflammatory (M1) or
anti-inflammatory (M2) functions (Tang and Le, 2016). As
already described, LPS (Kobayashi et al., 2013) and Aβ oligomers
(Maezawa et al., 2011; Shi et al., 2017; Taipa et al., 2017)
are potent inducers of microglia activation, characterized by
proliferation and polarization of the M1 microglial profile,
characterized by expression of NFκB and CD68 markers. In
this study, it was observed that apigenin was able to decrease
the percentage of CD68 and BrdU positive (proliferating)
microglia, as well as reduced the protein levels of IL-
6, OX42 and the gp130 (Type 1 cytokine receptor) after
inflammatory stimuli.
Likemicroglial cells, astrocytes respond to CNS injury, play an
important role in neuroinflammation, homeostasis impairment,
and synaptic dysfunction observed in AD (Verkhratsky et al.,
2010). As described by Ledo et al. (2013), intracerebroventricular
injection of Aβ oligomers in mice induces an increase in
astrocyte reactivity with increased expression of GFAP in the
hippocampus and cortex of these animals and increased levels
of proinflammatory cytokines. In the present study, the different
inflammatory stimuli induced changes in astrocyte morphology.
However, after treatment with apigenin, no morphological
characteristics of astrogliosis were visualized. The present study
reaffirms the immunomodulatory potential of apigenin and
the reduction of IL-1β-induced neuroinflammation, observed
through the downregulation of mRNA expression and protein
levels of IL-6 a proinflammatory cytokine. Associated with
the reduction of IL-6 we also observed a reduction in the
protein levels of gp130, identified as the β subunit of the
IL-6R complex. Thus, gp130-related cytokine plays an integral
role in inflammation (Jones et al., 2011). Similarly, Zhang X.
et al. (2014) demonstrated that apigenin (6.25, 12.5 and 25
µM) was able to inhibit the production of IL-6, IL-1β, and
CCL5 by human (THP-1) and mouse (J774A.1) macrophages
activated by LPS (100 ng/ml) by modulating intracellular
signaling pathways as mitogen-activated protein kinase
(MAPK), suppressing ERK1/2 phosphorylation and blocking
NF-κB activation. The same authors revealed that apigenin
suppressed IL-1β production by blocking the activation of
caspase-1 and disrupting assembly of the NLRP3 inflammasome
complex. Also, they observed that the downregulation of
IL-10 by LPS was reversed by apigenin, suggesting that
flavonoids may modulate the inflammatory response through
multiple mechanisms.
According to Tong et al. (2008), IL-1β interferes with
BDNF signaling by suppressing the activation of signal
transduction pathways (PI3-K/Akt and MAPK/ERK) that
is associated with neuronal survival. Thus, IL-1β makes
neurons vulnerable to degeneration by interfering with
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BDNF-induced neuroprotection. This neurotrophin also
plays a critical role in the pathophysiology of AD, in which
neuroinflammation is observed, and partly characterized
by increased pro-inflammatory cytokines such as IL-1β.
Zhang C. et al. (2014) showed that the deregulation of BDNF
signaling pathways correlates with synaptic loss and cellular
dysfunction underlying cognitive impairment in AD. Our
results revealed that apigenin was able to induce increase
BDNF mRNA levels in neuronal and glial cell co-cultures after
damage with IL-1β. These findings reaffirm the neuroprotective
effect of apigenin, as described by Zhao et al. (2013) which
demonstrated increased BDNF levels and the restoration of
learning deficits and cognitive function in apigenin-treated
2xTg-AD rats.
Taken together, our data suggest that apigenin at
a concentration of 1 µM has neuroprotective and
anti-inflammatory potential demonstrated in different
inflammatory models. Exacerbated inflammatory response
to different stimuli was observed, which was characterized by
the expression of high levels of proinflammatory cytokines
and chemokines, microglial proliferation, polarization to
M1 microglial profile and astrogliosis. Therefore, we suggest
that this neuroinflammation led to neurodegeneration, which
was attenuated by increased BDNF levels and modulation of the
inflammatory response as a consequence of apigenin treatment.
Finally, this is the first report of the interaction of flavonoid
apigenin in the co-culture of neurons and glial cells subjected
to IL-1β damage, correlating with AD. In the studies developed
by Choi et al. (2014), no neuroprotective effect of apigenin
was observed at 30 µM concentration in in vitro model of AD
using Aβ (25–35) at a concentration of 20 µM. However, in this
work, we demonstrated that apigenin in a lower concentration
had a neuroprotective and anti-inflammatory effect in different
neuroinflammation models.
Evidence indicates that IL-1β expression is one of the most
important neuropathological factors in ND, such as AD, being
recognized as a central factor in neuroinflammation (Azizi and
Mirshafiey, 2012; Xie et al., 2015). Second (Halle et al., 2008) the
activation of the NLRP3 inflammasome is closely associated with
caspase 1 activation and IL-1β release by Aβ-exposed microglia.
In a more recent study (Dempsey et al., 2017) analyzed the effect
of small NLRP3 inhibitor molecules calledMCC950 onmicroglia
cultures. MCC950 inhibited caspase-1 activation, stimulated Aβ
phagocytosis and reduced IL-1β expression in vitro. The same
study demonstrated, an in vivo model using 2xTg-AD mice,
that MCC950 (10 mg/kg) also inhibited NLRP3 and microglial
activation as well as reduced Aβ accumulation. Together,
these data suggest that Aβ accumulation may be mediated by
the formation of the inflammasome complex and induction
of IL-1β.
Thus, the search for new drugs aimed at blocking the
exacerbated formation of this complex and attenuating
neuroinflammation may prove to be a valuable strategy in
the treatment of ND, including AD. Thus, this work is a pioneer
in demonstrating the influence of apigenin on the protection
against deleterious effects induced by IL-1β in co-cultures of
neurons and glial cells.
CONCLUSION
We have shown that apigenin presents neuroprotective
and neuroimmunomodulatory effects in in vitro models of
neuroinflammation. Thus, might represent a potential agent for
the treatment of neurodegenerative conditions.
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